929622-21-9Relevant articles and documents
Novel benzamide-based histamine H3 receptor antagonists: The identification of two candidates for clinical development
Letavic, Michael A.,Aluisio, Leah,Apodaca, Richard,Bajpai, Manoj,Barbier, Ann J.,Bonneville, Anne,Bonaventure, Pascal,Carruthers, Nicholas I.,Dugovic, Christine,Fraser, Ian C.,Kramer, Michelle L.,Lord, Brian,Lovenberg, Timothy W.,Li, Lilian Y.,Ly, Kiev S.,McAllister, Heather,Mani, Neelakandha S.,Morton, Kirsten L.,Ndifor, Anthony,Nepomuceno, S. Diane,Pandit, Chennagiri R.,Sands, Steven B.,Shah, Chandra R.,Shelton, Jonathan E.,Snook, Sandra S.,Swanson, Devin M.,Xiao, Wei
, p. 450 - 454 (2015/04/27)
The preclinical characterization of novel phenyl(piperazin-1-yl)methanones that are histamine H3 receptor antagonists is described. The compounds described are high affinity histamine H3 antagonists. Optimization of the physical properties of these histamine H3 antagonists led to the discovery of several promising lead compounds, and extensive preclinical profiling aided in the identification of compounds with optimal duration of action for wake promoting activity. This led to the discovery of two development candidates for Phase I and Phase II clinical trials.
